News Digest / Ticker: DYN

Ticker: DYN

09:05am, Monday, Dec 08, 2025

Dyne Therapeutics Shares Jump Following Strong DMD Trial Outcomes

Dyne Therapeutics (NASDAQ:DYN) gains 7% after positive Phase 1/2 DELIVER trial results for Z-Rostudirsen in Duchenne Muscular Dystrophy, showing significant dystrophin increase and sustained functional improvements.